New Retina Radio
New Retina Radio

02.22.24

The State of Biosimilars: How We Got Here and What It Means for Practice

Two biosimilars are approved for use in retina by the US FDA—and more will be approved in the coming years. What exactly are biosimilars? What benefit might they provide? And how confident are retina specialist that biosimilars will deliver safe, high-quality care?  Moderator John Kitchens, MD, sits down with retina specialists Carl Awh, MD, and Firas Rahhal, MD, to answer these questions, and to ask whether the economic realities of biosimilars make them a good choice for modern retina practices.  This podcast is editorially independent, supported with advertising by Sandoz. 

View full description +

MORE EPISODES

02.05.26

What I Wish I Knew: Insights From the Next Generation of Retina Specialists

Nemo Patel, MD; Sam Minaker, MD; and Has Al-khersan, MD

02.05.26

Practical Insights on Adopting FDA-Approved Treatments Into Practice

Nemo Patel, MD; Danny Mammo, MD; and Matthew Donovan, MD

02.05.26

The Race to Slow GA: A Retina Specialist in the Driver’s Seat of GA Treatment

Nemo Patel, MD and Patrick Staropoli, MD

01.15.26

New Retina Radio Journal Club w/ VBS: Diagnosis Delays in Stargardt Disease

Alexis Warren, MD; Jesse Sengillo, MD; and Sruthi Arepalli, MD

01.08.26

The Fellow Eye: Episode 1

David Fell MD; Justin Muste, MD; Flavius Beca, MD

12.18.25

New Retina Radio Journal Club w/ VBS: Assessing Surgical Competency Among Retina Fellows: Perspectives from Directors and Graduates

Nikisha Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD

12.09.25

DME, DR, and Next-Generation Therapies

David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD

12.09.25

Wet AMD and Next-Generation Therapies

David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD

Show More